Overview

Treatment of Adult Ph+ LAL With BMS-354825

Status:
Completed

Trial end date:
2008-09-01

Target enrollment:

Participant gender:

Summary

The primary objective of the trial is to estimate the activity of BMS-354825 (Dasatinib) in de novo adult Ph+ ALL patients in terms of hematological complete remission (HCR) rate.

Phase:

Phase 2

Details

Lead Sponsor:

Gruppo Italiano Malattie EMatologiche dell'Adulto

Treatments:

Dasatinib